Publicacións nas que colabora con Ana Mariño (35)

2024

  1. Elevated plasma levels of IP-10 and MIG are early predictors of loss of control among elite HIV controllers

    Frontiers in Immunology, Vol. 15

2023

  1. IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors

    Frontiers in Immunology, Vol. 14

  2. Interleukin 18 (IL-18) and IL-3 in Extracellular Vesicles: Biomarkers for Durable Elite Control of HIV-1

    Journal of Infectious Diseases

2022

  1. Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control

    The Journal of infectious diseases, Vol. 225, Núm. 6, pp. 1040-1049

  2. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

  3. Viruses Previously Identified in Brazil as Belonging to HIV-1 CRF72_BF1 Represent Two Closely Related Circulating Recombinant Forms, One of Which, Designated CRF122_BF1, Is Also Circulating in Spain

    Frontiers in Microbiology, Vol. 13

2019

  1. Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain

    Frontiers in Microbiology, Vol. 10, Núm. APR

  2. Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide

    Infection, Vol. 47, Núm. 1, pp. 115-119

2018

  1. Cure of chronic hepatitis C virus infection in an HIV-coinfected patient with multiple comorbidities and drug interaction challenges

    International Journal of STD and AIDS, Vol. 29, Núm. 9, pp. 933-936

  2. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies

    Journal of Medical Virology, Vol. 90, Núm. 6, pp. 1094-1098

  3. Recurrent coronary disease in HIV-infected patients: role of drug–drug interactions

    British Journal of Clinical Pharmacology, Vol. 84, Núm. 7, pp. 1617-1619

2017

  1. Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure

    Journal of Medical Virology, Vol. 89, Núm. 7, pp. 1304-1308

  2. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. European mitochondrial haplogroups impact on liver fibrosis progression among HCV and HIV/HCV-coinfected patients from Northwest Spain

    Journal of Acquired Immune Deficiency Syndromes, Vol. 73, Núm. 2, pp. 149-153

  2. Immune reconstitution inflammatory syndrome in an HIV-infected patient using subcutaneous silicone fillers

    AIDS, Vol. 30, Núm. 16, pp. 2561-2563

  3. Sequence analysis of in vivo-expressed HIV-1 spliced RNAs reveals the usage of new and unusual splice sites by viruses of different subtypes

    PLoS ONE, Vol. 11, Núm. 6

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  2. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study

    HIV Medicine, Vol. 16, Núm. 10, pp. 628-634

  3. Phylogeny and phylogeography of a recent HIV-1 subtype F outbreak among men who have sex with men in Spain deriving from a cluster with a wide geographic circulation in Western Europe

    PLoS ONE, Vol. 10, Núm. 11

2014

  1. Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects

    Antiviral Research, Vol. 104, Núm. 1, pp. 59-61